Clinical trial · Observational
Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)
A Retrospective Pooled Analysis of Complete Remission Among Pediatric Patients With Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
NCT02303522CI-TRIAL-00044973completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An historical data comparator study for children with relapsed/refactory acute lymphoblastic leukemia (ALL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Acute Lymphoblastic Leukemia | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Other: not applicable - observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All subjects
- description
- All subjects will be included in a unique cohort
- interventionNames
- Other: Other: not applicable - observational study
Primary outcomes (1)
- measure
- Hematological Complete Remission (CR)
- timeFrame
- Approx. 1 year
- description
- To estimate hematological Complete Remission (CR) in pediatric patients with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL)
Secondary outcomes (5)
- measure
- Overall survival
- timeFrame
- Approx. 1 year
- description
- OS following salvage therapy: defined as time to death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion criteria: * Pediatric (age less than 18 years) patients with relapsed or refractory B-cell precursor ALL, specifically those with * 2nd or later relapse after chemotherapy (with no prior transplantation), * Relapse after HSCT, or * Refractory disease * Had treatment for relapsed or refractory disease between 2005-2012 * Has data available on ALL treatment, including number of salvage treatments, response status after therapies, and HSCT Exclusion criteria: * No CNS involvement at relapse * No previous treatment with blinatumomab
References
Publications (0)
Data not yet available
No reference posted for this study.